| RT as scheduled | Late missed RT | Early missed RT | Entire cohort | p value |
---|---|---|---|---|---|
Number | 448 | 341 | 116 | 905 | Â |
Sex, n (%) | Â | Â | Â | Â | 0.210 |
 Women | 26 (5.8%) | 21 (6.2%) | 12 (10.3%) | 59 (6.5%) |  |
 Men | 422 (94.2%) | 320 (93.8%) | 104 (89.7%) | 846 (93.5%) |  |
Age (years), median (range) | 50.8 (25.1–89.4) | 51.1 (28.0–83.6) | 49.8 (25.1–78.8) | 50.8 (25.1–89.4) | 0.330 |
Age (years), n (%) | Â | Â | Â | Â | 0.481 |
  < 60 | 363 (81.0%) | 274 (80.4%) | 95 (81.9%) | 732 (80.9%) |  |
  ≥ 60 | 85 (19.0%) | 67 (19.6%) | 21 (18.1%) | 173 (19.1%) |  |
Differentiation | Â | Â | Â | Â | 0.305 |
 Well differentiated | 104 (23.2%) | 87 (25.5%) | 40 (34.5%) | 232 (25.6%) |  |
 Moderately differentiated | 284 (63.4%) | 199 (58.4%) | 62 (53.5%) | 545 (60.2%) |  |
 Poorly differentiated | 60 (13.4%) | 55 (16.1%) | 14 (12.0%) | 128 (14.2%) |  |
pStage, n (%) | Â | Â | Â | Â | 0.710 |
 Stage I | 6 (1.3%) | 2 (0.6%) | 0 (0%) | 8 (0.9%) |  |
 Stage II | 16 (3.6%) | 11 (3.2%) | 2 (1.7%) | 29 (3.2%) |  |
 Stage III | 123 (27.5%) | 100 (29.3%) | 33 (28.4%) | 256 (28.3%) |  |
 Stage IV | 303 (67.6%) | 228 (66.9%) | 81 (69.8%) | 612 (67.6%) |  |
pT − Stage, n (%) |  |  |  |  | 0.824 |
 T1/2 | 58 (12.9%) | 40 (11.7%) | 16 (13.8%) | 114 (12.6%) |  |
 T3/4 | 390 (87.1%) | 301 (88.3%) | 100 (86.2%) | 791 (87.4%) |  |
pN − Stage, n (%) |  |  |  |  | 0.828 |
 N0/1 | 255 (56.9%) | 198 (58.0%) | 63 (54.3%) | 516 (57.0%) |  |
 N2/3 | 193 (43.1%) | 143 (42.0%) | 53 (45.7%) | 389 (43.0%) |  |
RTT (days), median (range) | 46 (39–53) | 49 (44–56) | 50 (43–56) | 47 (39–56) | 0.131 |
 Mean ± SD | 45.6 ± 2.52 | 49.0 ± 2.77 | 50.3 ± 2.94 | 47.5 ± 3.28 | 0.120 |
S/RT interval (days), median (range) | 39 (15–106) | 40 (15–94) | 37 (17–77) | 39 (15–106) | 0.078 |
 Mean ± SD | 40.2 ± 12.2 | 41.6 ± 13.4 | 38.4 ± 10.4 | 40.5 ± 12.5 | 0.061 |
S/RT interval (days), n (%) | Â | Â | Â | Â | 0.256 |
  ≤ 42 | 326 (72.8%) | 231 (67.7%) | 85 (73.3%) | 642 (70.9%) |  |
  > 42 | 122 (27.2%) | 110 (32.3%) | 31 (26.7%) | 263 (29.1%) |  |
TPT (days), median (range) | 84 (50–152) | 88 (63–143) | 86 (65–128) | 86 (59–152) | 0.058 |
 Mean ± SD | 85.8 ± 12.4 | 90.5 ± 13.8 | 88.6 ± 10.7 | 88.0 ± 12.9 | 0.029 |
TPT (days), n (%) |  |  |  |  | < 0.001 |
  ≤ 85 | 254 (56.7%) | 133 (39.0%) | 49 (42.2%) | 436 (48.2%) |  |
  > 85 | 194 (43.3%) | 208 (61.0%) | 67 (57.7%) | 469 (51.8%) |  |
RT techniques | Â | Â | Â | Â | 0.691 |
 2D RT | 76 (16.9%) | 68 (19.9%) | 20 (17.2%) | 164 (18.1%) |  |
 3D conformal RT | 43 (9.6%) | 14 (4.1%) | 12 (10.3%) | 69 (7.6%) |  |
 IMRT | 296 (66.1%) | 223 (65.4%) | 80 (70.0%) | 599 (66.2%) |  |
 VMAT | 33 (7.4%) | 36 (10.6%) | 4 (3.5%) | 73 (8.1%) |  |
Chemotherapy, n (%) | Â | Â | Â | Â | 0.933 |
 Yes | 248 (55.4%) | 190 (55.7%) | 67 (57.8%) | 505 (55.8%) |  |
 No | 200 (44.6%) | 151 (44.3%) | 49 (42.2%) | 400 (44.2%) |  |
PET imaging, n (%) | Â | Â | Â | Â | 0.095 |
 Yes | 233 (52.0%) | 151 (44.3%) | 58 (50.0%) | 442 (48.8%) |  |
 No | 215 (48.0%) | 190 (55.7%) | 58 (50.0%) | 463 (51.2%) |  |
Smoking, n (%) | Â | Â | Â | Â | 0.864 |
 No | 65 (14.5%) | 46 (13.5%) | 18 (15.5%) | 129 (14.3%) |  |
 Yes | 383 (85.5%) | 295 (86.5%) | 98 (84.5%) | 776 (85.7%) |  |
Betel quid chewing, n (%) | Â | Â | Â | Â | 0.366 |
 No | 94 (21.0%) | 85 (24.9%) | 29 (25.0%) | 208 (23.0%) |  |
 Yes | 354 (79.0%) | 256 (75.1%) | 87 (75.0%) | 697 (77.0%) |  |
Alcohol use, n (%) | Â | Â | Â | Â | 0.171 |
 No | 182 (40.6%) | 116 (34.0%) | 43 (37.1%) | 341 (37.7%) |  |
 Yes | 266 (59.4%) | 225 (66.0%) | 73 (62.9%) | 564 (62.3%) |  |
Comorbidities, n (%) | Â | Â | Â | Â | 0.227 |
 No | 237 (52.9%) | 159 (46.6%) | 61 (52.6%) | 456 (50.3%) |  |
 Yes | 211 (47.1%) | 182 (53.4%) | 55 (47.4%) | 448 (49.5%) |  |